Cancer Network presents exclusive coverage from the American Society of Clinical Oncology (ASCO) 2013 Genitourinary Cancers Symposium. Check out the stories below for write-ups of the most important information to come out of this year's event.
Cancer Network presents exclusive coverage from the American Society of Clinical Oncology (ASCO) 2013 Genitourinary Cancers Symposium. Check out the stories below for write-ups of the most important information to come out of this year's event.
Longer Surgery Delay After CRT Does Not Improve Esophageal Cancer Responses
September 23rd 2023Data from the NeoRes II trial caution against routinely delaying surgery for more than 6 weeks after patients with resectable locally advanced esophageal cancer receive neoadjuvant chemoradiotherapy.
Ribociclib/Aromatase Inhibitors Maintain HRQOL in HR+, HER2– Breast Cancer
September 22nd 2023A health-related quality of life analysis of the phase 3 NATALEE trial supports the risk/benefit profile of adding ribociclib to nonsteroidal aromatase inhibitors in patients with hormone receptor–positive, HER2-negative early breast cancer.
Elacestrant Earns EU Approval for ESR1+, ER+, HER2– Advanced Breast Cancer
September 22nd 2023The regulatory decision to approve elacestrant in European patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer and an activating ESR1 mutation was based on data from the phase 3 EMERALD study.
2 Clarke Drive
Cranbury, NJ 08512